Sunday, April 30, 2017

Natco Pharma - Buy on declines



Company Background

Natco Pharma Limited is a pharmaceutical company. The Company is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The Company's segments include active pharmaceuticals ingredient, finished dosage formulations, job works, pharmacy and others. 

The Company's product categories include Domestic Formulations, International Formulations, API's and Blockbusters. The Company's products include Alphalan, Bandrone, Bendit, Clokeran, Lenalid, Thioplan, Anastronat, Capnat, Fulvenat, Kabanat, Natdox-LP, Rapact, Temonat, X-Trant, Glatimer, Hepcinat, Natdac, Natzold, Tigi, Alprazolam, Chloroquine Phosphate, Lansoprazole, Letrozole, Granisetron, Rizatriptan IR, Imatinib, Salmeterol Xinafoate, Sertraline Form I, Ibandronate Sodium Monohydrate, Pantoprazole Sodium Sesquihydrate, Ondansetron Hydrochloride (Injectable Grade), Daclatasvir and Glatiramer Acetate. The Company manufactures over 20 products under contract.

Stock Performance:

During the last one year the scrip has given a decent 128% return jumping from 453 to current 923 after touching Rs.1015 levels which is 52 week high.

Recommendation :
Buy on declines of around Rs.900 and hold for a target price of Rs.1400 holding period of 12 months


Smart Investor -
Equity Research


No.24 Pattamal Plaza
3rd Cross Kammanahalli
BANGALORE 560084
Smart Investor
Smart Investor

Mail - intellinvestor@gmail.com

No comments:

Post a Comment